lifestyle.sourcefed.com

Author: Revelation Biosciences, Inc.

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

April 6, 2026
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

March 30, 2026
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 19, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 27, 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

January 26, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

January 24, 2026
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

January 21, 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

January 14, 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

January 7, 2026